Developmental medicine and child neurology
-
Dev Med Child Neurol · Aug 2020
Observational StudyProfile of hospital admissions for adults with cerebral palsy: a retrospective cohort study.
To retrospectively profile acute hospital admissions for a defined cohort of adults with cerebral palsy (CP). ⋯ Adults with CP predominantly access acute hospital services for emergency health care. A high frequency of admissions is associated with respiratory illness and gastrostomy dysfunction in adults with CP. What this paper adds Adults with cerebral palsy (CP) access acute inpatient services for emergency health care. Hospital admissions are predominantly because of respiratory illness and gastrostomy dysfunction. Admission length of stay is longer for adults than children. Many adults with CP require hospitalization more than once a year.
-
Dev Med Child Neurol · Nov 2019
Measuring ambulation with wrist-based and hip-based activity trackers for children with cerebral palsy.
To assess the accuracy of consumer available wrist-based and hip-based activity trackers in quantitatively measuring ambulation in children with cerebral palsy (CP). ⋯ Consumer available activity trackers accurately measure ambulation in children with cerebral palsy (CP). The hip-based tracker is more accurate than the wrist-based tracker for children with CP. The hip-based Fitbit activity tracker accurately measures step counts of children with CP during ambulation.
-
Dev Med Child Neurol · Jan 2019
ReviewProtection of brain development by antenatal magnesium sulphate for infants born preterm.
Cerebral palsy (CP) remains the most significant neurological disorder associated with preterm birth. It disrupts quality of life and places huge cost burdens on society. Antenatal magnesium sulphate administration to females before 32 weeks' gestation has proven to be an effective intervention to reduce the rate of CP. ⋯ WHAT THIS PAPER ADDS: Neuroprotective effect of magnesium sulphate to reduce cerebral palsy in infants born preterm when administered to females at risk of imminent preterm birth. Neuroprotection regardless of gestational age, cause of preterm birth, and total dose. Antenatal magnesium sulphate treatment has good cost-effectiveness.